allergic reaction; contact dermatitis; rash; this is a spontaneous report received from a contactable reporter(s) (consumer or other non hcp) from the regulatory agency (ra). the reporter is the patient. regulatory number: gb-mhra-webcovid-202202171828053490-ancrb (ra). other case identifier(s): gb-mhra-adr 26614753 (ra). a 35-year-old female patient received bnt162b2 (comirnaty), administration date 01feb2022 (batch/lot number: unknown) as dose 3 (booster), single for covid-19 immunisation. the patient's relevant medical history and concomitant medications were not reported. patient has not had symptoms associated with covid-19 and not had a covid-19 test. patient was not pregnant, was not currently breastfeeding and was not enrolled in clinical trial. vaccination history included: bnt162b2 (dose: 1), for covid-19 immunization; bnt162b2 (dose: 2), for covid-19 immunization. the following information was reported: hypersensitivity (medically significant), outcome "not recovered", described as "allergic reaction"; rash (medically significant) with onset 02feb2022, outcome "recovering", described as "rash"; dermatitis contact (medically significant), outcome "unknown", described as "contact dermatitis". the clinical course was reported as follows: severe rash developed similar to contact dermatitis. reported to hospital sent by gp and they said the patient was experiencing an allergic reaction to something from her blood results. patient has not tested positive for covid-19 since having the vaccine. this report was not related to possible inflammation of the heart (myocarditis or pericarditis). no follow-up attempts are possible; information about lot/batch number cannot be obtained. no further information is expected

test name: blood tests; result unstructured data: test result:patient was experiencing an allergic reaction to; comments: something

na

na